Thrombozytenfunktionshemmer zur Sekundärprophylaxe des ischämischen zerebralen Insults – Leitliniengerechte Basismaßnahme

Der Einsatz von Thrombozytenfunktionshemmern ist – sofern keine Kontraindikationen vorliegen – Basismaßnahme der sekundärpräventiven Therapie bei Schlaganfallpatienten. In den aktuellen Leitlinien der Deutschen Gesellschaft für Neurologie (DGN) und der Deutschen Schlaganfall-Gesellschaft (DSG) wird ein risikoadaptierter Therapieansatz mit Thrombozytenfunktionshemmern empfohlen [1]. Im Folgenden werden die wichtigsten Empfehlungen der Leitlinien zu diesem Thema vorgestellt.

In stroke patients, a basic need of secondary preventive therapy is the use of thrombocyte function inhibitors, provided there are no contraindications. Current guidelines issued by the German Society of Neurology (DGN) and the German Society of Stroke (DSG) recommend a risk-adapted therapeutic approach with platelet inhibitors [1]. The most important recommendation given in these guidelines on this subject are presented herewith.

Key words

ischemic stroke - secondary prevention - risk of second stroke - platelet inhibitor

Literatur

• 1 Leitlinien der DGN 2008. Primär- und Sekundärprävention der zerebralen Ischämie. Gemeinsame Leitlinien der Deutschen Gesellschaft für Neurologie (DGN) und der deutschen Schlaganfallgesellschaft (DSG).  www.dsg-info.de/pdf/ll08kap.pdf
• 2 Hill MD, Yiannakoulias N, Jeerakathil T. et al. . The high risk of stroke immediately after transient ischemic attack: a population-based study.  Neurology. 2004;  62 2015-2020
• 3 Lovett J, Coull A, Rothwell P.. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies.  Neurology. 2004;  62 569-573
• 4 Antithrombotic Trialists' Collaboration. . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
• 5 Ringleb P, Bhatt D, Hirsch A. et al. . Benefit of clopidogrel over aspirin is amplified in patients with a history of ischaemic events.  Stroke. 2004;  35 528-532
• 6 Diener HC.. Modified-release dipyridamole combined with aspirin for secondary stroke prevention.  Aging Health. 2005;  1 19-26
• 7 Weimar C, Diener HC, Alberts MJ. et al. . The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry.  Stroke. 2009;  40 350-354
• 8 National Institute for Health and Clinical Excellence. .Technology Appraisal Guidance 90: Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events. download unter www.nice.org.uk/TA 090: 2005
• 9 Algra A, van Gijn J.. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin.  J Neurol Neurosurg Psychiatry. 1999;  65 255
• 10 Topol E, Easton D, Harrington R. et al. . Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.  Circulation. 2003;  108 399-406
• 11 Yussuf S, Zhao F, Mehta SR. et al. . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med. 2000;  345 494-502
• 12 Diener HC, Cunha L, Forbes C. et al. . European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.  J Neurol Sci. 1996;  143 1-13
• 13 Diener HC, Forbes C, Riekkinen PJ. et al. . European Stroke Prevention Study 2: Efficacy and safety data.  J Neurol Sci. 1997;  1
• 14 Diener HC, Darius H, Bertrand-Hardy JM. et al. . Cardiac safety in the European stroke prevention study 2 (ESPS2).  Int J Clin Pract. 2001;  55 162-163
• 15 CAPRIE Steering Committee. . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet. 1996;  348 1329-1339
• 16 Diener H, Bogousslavsky J, Brass L. et al. . Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.  Lancet. 2004;  364 331-337
• 17 Diener HC, Sacco RL, Yusuf S. et al. . Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.  Lancet Neruol. 2008;  7 875-884

1 Clopidogel versus Aspirin in Patients at Risk of Ischaemic Events

2 Europäische Schlaganfall PräventionsStudie

3 Management of ATherothrombosis with Clopidogrel in High risk patients

4 Prevention Regimen For Effectively avoiding Second Strokes

Korrespondenz